Treatment Options for Recurrent Ovarian Cancer with Multiple Genetic Mutations

Introduction to Treatment Options

The National Comprehensive Cancer Network recommends platinum-based combination chemotherapy as the preferred first-line treatment for platinum-sensitive recurrent disease (Category 1) 2, 3
Patients with platinum-sensitive disease have more treatment options and generally better outcomes than those with platinum-resistant disease 1, 2

Platinum sensitivity is a key determinant in treatment selection, with platinum-sensitive disease defined as recurrence more than 6 months after primary treatment, while platinum-resistant disease recurs within 6 months 1, 2

Platinum-based combination chemotherapy is the preferred first-line treatment for platinum-sensitive recurrent disease (Category 1) 2, 3
Recommended platinum-based combinations include carboplatin/paclitaxel (Category 1) 2, carboplatin/weekly paclitaxel 2, carboplatin/docetaxel 2, carboplatin/gemcitabine (shown to improve progression-free survival) 2, and carboplatin/liposomal doxorubicin (also shown to improve progression-free survival) 2
Single non-platinum agents are recommended for platinum-resistant disease 1, 3
Preferred single agents include docetaxel 1, oral etoposide 1, gemcitabine 1, liposomal doxorubicin 1, weekly paclitaxel 1, and topotecan 1

PARP inhibitors are strongly recommended for patients with BRCA2 mutations who have responded to platinum-based therapy (Category 1) 4, 5
Current FDA-approved PARP inhibitors for recurrent disease with BRCA mutations include olaparib 300 mg every 12 hours 5, 6, rucaparib 600 mg every 12 hours 5, 6, and niraparib 200-300 mg once daily 5, 6
PARP inhibitor use is now limited to patients with BRCA1/2 mutations in the recurrent setting following FDA revisions 7, 8
PARP inhibitors exploit synthetic lethality in cells with deficient homologous recombination repair (HRR), which is particularly relevant for patients with BRCA2 mutations 9
Single-agent bevacizumab (10 mg/kg every 2 weeks) is a reasonable option for patients with recurrent disease that is platinum-resistant 3
Bevacizumab is active (21% response rate) in both platinum-sensitive and platinum-resistant disease 3

BRCA2 mutation is the most clinically actionable mutation in this patient and strongly predicts response to PARP inhibitors 9, 4
The combination of mutations suggests genomic instability that may further increase sensitivity to PARP inhibitors 9

For BRCA2-mutated platinum-sensitive disease, first choice is platinum-based combination therapy followed by PARP inhibitor maintenance 2, 5
For BRCA2-mutated platinum-resistant disease, first choice is PARP inhibitor monotherapy if PARP inhibitor-naïve 5, 6
Alternative options for BRCA2-mutated platinum-resistant disease include single-agent non-platinum chemotherapy (docetaxel, liposomal doxorubicin, weekly paclitaxel, etc.) 1 and bevacizumab 3

Monitor for common PARP inhibitor adverse effects including hematologic toxicities (thrombocytopenia, neutropenia, anemia) 7, fatigue and gastrointestinal symptoms 5
Dose adjustments may be necessary to manage toxicities while maintaining treatment 5

Secondary cytoreductive surgery may be considered for patients with recurrence after a long disease-free interval (≥6 months) 2
Clinical trials should be considered at all stages of treatment, especially for patients with multiple mutations that may respond to targeted therapies 1